A multicenter, phase II study of soluble LAG-3 (Eftilagimod alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC)
Peguero, JA Bajaj, P Carcereny, E Clay, TD Doger, B Felip, E Krebs, Matthew G Forster, M Aix, SP Roxburgh, P
Peguero, JA
Bajaj, P
Carcereny, E
Clay, TD
Doger, B
Felip, E
Krebs, Matthew G
Forster, M
Aix, SP
Roxburgh, P
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Peguero JA, Bajaj P, Carcereny E, Clay TD, Doger B, Felip E, et al. A multicenter, phase II study of soluble LAG-3 (Eftilagimod alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2019;37(15_suppl):TPS2667-TPS.